naltrexone has been researched along with Overweight in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (9.52) | 29.6817 |
| 2010's | 16 (76.19) | 24.3611 |
| 2020's | 3 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Argyrakopoulou, G; Bontozoglou, N; Kalra, B; Kokkinos, A; Konstantinidou, SK; Kouvari, M; Kumar, A; Kumar, M; Kyriakopoulou, K; Mantzoros, CS; Simati, S; Stefanakis, K | 1 |
| Acevedo-Mackey, D; Acharjee, N; Akhtar, K; Al-Buriahi, MS; Amandi, A; An, Y; Anjum, NA; Asgari, Q; Badiei, B; Baez Vasquez, AY; Bagley, GD; Bahreini, MS; Bajelan, S; Baluja, MQ; Barbieri, MA; Batalha, MA; Bettiol, H; Bhattarai, U; Biset, JC; Bjerg, M; Björnsson, BT; Boag, AM; Borthwick, MS; Boukhris, I; Bragança, MLBM; Breves, JP; Britz-McKibbin, P; Broaddus, RR; Burnell, JE; Camargo, CA; Campo, M; Carlsen, KL; Catchpole, B; Cavalli, L; Chai, C; Chanakya, HN; Chang, AYH; Chantada, A; Chen, W; Chen, X; Chen, Y; Cheng, ZL; Chenoweth, DA; Chhetri, S; Coelho, CCNDS; Coker, ES; Cole, MA; Coniglio, A; Connor, TR; Corbishley, A; D'Arienzo, M; da Silva, AAM; Dai, Y; de Oliveira, BR; Dignac, MF; Dong, A; Dottino, JA; Duo, J; Einarsdottir, IE; Ekanayake, EMDNK; El Fels, L; El Hayany, B; El Shahawy, O; Elliott, RJR; Fabrizi, E; Farkas, K; Fellman, B; Fenoglio, D; Ferrario, M; Flögel, F; Fujiogi, M; Gamage, BD; Ganson, KT; Gao, X; Gärtner, S; Gautam, A; Gautam, S; Gaze, WH; Gosse, JA; Graham, DW; Graham, PA; Guastella, G; Guerrero, S; Gul, M; Guo, B; Guo, X; Gupta, VK; Hafidi, M; Halland, A; Han, W; Hardisty, M; Hasegawa, K; Hess, ST; Heydari, R; Hillary, LS; Holm, R; Huang, L; Jaleh, B; Jayasundara, JASB; Ji, X; Jiang, L; Jones, DL; Kac, G; Kebaili, I; Kelley, JB; Kelum, SHP; Kennedy, LJ; Khan, NA; Khazalpour, S; Khuntia, HK; Kinney, MS; Kommedal, Ø; Koomhin, P; Krawczyk, N; Kæstel, T; Lakmal, MAC; Li, H; Li, K; Li, R; Li, S; Li, W; Li, X; Li, Y; Liang, L; Lin, Y; Lippo, E; Liu, B; Liu, F; Liu, J; Liu, X; Liu, Y; Lodha, D; Loose, DS; López-Meza, P; Lu, F; Lu, KH; Lu, Y; Luo, Y; Ma, B; Malham, SK; Masood, A; Matan, N; McCormick, SD; McDonald, JE; McKenzie, LJ; Melendez, BD; Mikaeili, F; Mir, IR; Mirjalili, MH; Moreno, KP; Moura, IB; Müller, S; Nagata, JM; Nasri, A; Nasrollahzadeh, M; Navarro-Jiménez, E; Nie, E; Nielsen, CU; Nielsen, S; Nøhr, MK; Obeng, B; Odetayo, AA; Ortiz-Barrios, M; Ozgen, C; Pan, X; Parisi, ML; Paskavitz, AL; Patel, AK; Pedersen, M; Pontarollo, N; Potts, CM; Price, C; Pu, Y; Quénéa, K; Rahimi Khonakdari, M; Rather, BA; Raut, P; Regish, AM; Reible, DD; Rezadoost, H; Rizzati, M; Roviello, GN; Roviello, V; Rumpel, C; Sang, J; Sangroula, S; Saraiva, MDCP; Sarker, A; Sayyed, MI; Segoshi, A; Sehar, Z; Shao, X; Shaw, D; Shaw, L; Shekhawat, NS; Shim, JK; Shokouhimehr, M; Short, A; Soliman, PT; Songsamoe, S; Springer-Miller, RH; Stenstad, T; Strobl, E; Sun, R; Syme, H; Thai, L; Tian, G; Tofighi, B; Tonguc, B; Tuyiringire, D; Ulaganathan, N; Ulvestad, E; Varacca, A; Vergalli, S; Verma, DK; Villmones, HC; Wang, D; Wang, H; Wang, J; Wang, L; Wang, M; Wang, S; Wang, Y; Wang, Z; Weedon-Fekjær, H; Weller, SR; West, BE; Wilcox, MH; Wu, W; Wufuer, R; Xia, S; Xiang, H; Xu, H; Yan, L; Yang, RK; Yang, Y; Yates, MS; Ye, Q; Yin, H; Yin, Y; Yuan, Y; Yucesan, M; Yue, W; Zeng, W; Zhang, C; Zhang, D; Zhang, H; Zhang, L; Zhang, Q; Zhang, Y; Zhou, B; Zhou, Y; Zhu, Y; Zhu, Z | 1 |
| Lee, SY; Tak, YJ | 1 |
| Dunayevich, E; Guerdjikova, AI; Halseth, AE; McElroy, SL; Shan, K; Walsh, B | 1 |
| Acevedo, LM; Apovian, CM; Dunayevich, E; Greenway, FL; McElroy, SL; Pi-Sunyer, X | 1 |
| Apovian, CM; Aronne, L; Burns, C; Dunayevich, E; Kim, D; Rubino, D; Still, C; Wyatt, H | 1 |
| Howland, RH | 1 |
| Guloksuz, S; Reutenauer, EL; Srihari, VH; Tek, C | 1 |
| Bays, H; Burns, C; Fujioka, K; Greenway, F; Gupta, AK; Hollander, P; Klassen, P; Plodkowski, R | 1 |
| Adam, T; Dallman, M; Daubenmier, J; Epel, E; Hecht, FM; Kristeller, J; Lustig, RH; Woolley, J | 1 |
| Nau, JY | 1 |
| Greig, SL; Keating, GM | 1 |
| Bakris, G; Buse, JB; Nissen, SE; Perez, A; Prcela, L; Smith, SR; Wadden, T; Wolski, KE | 1 |
| Dybala, C; Foreyt, JP; Halseth, AE; Herrmann, K; Hong, K; Lam, H | 1 |
| Braverman-Panza, J; Fujioka, K | 1 |
| Anderson, JW; Atkinson, RL; Cowley, MA; Dunayevich, E; Fujioka, K; Gadde, KM; Greenway, FL; Gupta, AK; Guttadauria, M; O'Neil, P; Schumacher, D; Smith, D; Tollefson, GD; Weber, E; Whitehouse, MJ | 1 |
| Billes, SK; Dunayevich, E; Erickson, JS; Katz, BB; Oskooilar, N; Tollefson, G; Wilcox, CS | 1 |
| Dunayevich, E; Erickson, J; Fujioka, K; Greenway, FL; Guttadauria, M; Kim, DD; Mudaliar, S; Plodkowski, RA | 1 |
| Billes, SK; Greenway, FL | 1 |
| Mercer, SL | 1 |
| McKee, SA; O'malley, SS; White, MA | 1 |
5 review(s) available for naltrexone and Overweight
| Article | Year |
|---|---|
Topics: Acyclic Monoterpenes; Adipose Tissue; Adolescent; Adult; Aged; Aged, 80 and over; Air Pollutants; Air Pollutants, Occupational; Amino Acid Transport Systems; Analgesics, Opioid; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Arthrobacter; Bacteria; Bacteriological Techniques; Benzaldehydes; Biodegradation, Environmental; Biofilms; Biological Transport; Biomarkers; Biomass; Bioreactors; Body Composition; Body Mass Index; Brassica; Brazil; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Caco-2 Cells; Cadmium; Calcium; Calcium Carbonate; Calcium Channels; Catalysis; Cell Degranulation; Cell Line; Cell Membrane; Chitosan; Chromatography, High Pressure Liquid; Chromium; Cobalt; Cohort Studies; Colony Count, Microbial; Composting; Copper; COVID-19; Cross-Sectional Studies; Cytoplasm; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Diarrhea; Diethylhexyl Phthalate; Dose-Response Relationship, Drug; Drug Implants; Drug Stability; Drug Synergism; Electroplating; Endometrial Neoplasms; Endometrium; Environmental Monitoring; Environmental Restoration and Remediation; Estradiol; Estrogens; Feces; Female; Food Microbiology; Food Preservation; Fruit and Vegetable Juices; Gasotransmitters; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gene Expression Regulation, Developmental; Genetic Predisposition to Disease; Glutathione; Gold; Graphite; Growth Hormone; Harm Reduction; Hot Temperature; Humans; Hydrocortisone; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydrogen-Ion Concentration; Ileum; Imidazoles; Injections, Intraperitoneal; Insecticides; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor Binding Protein 2; Insulin-Like Growth Factor Binding Protein 5; Insulin-Like Growth Factor I; Intestinal Absorption; Light; Lignin; Liver; Magnetics; Male; Manganese; Mast Cells; Melanoma; Membrane Potentials; Metals; Methadone; Microbial Viability; Microplastics; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Middle Aged; Mitochondrial Swelling; Molecular Dynamics Simulation; Monophenol Monooxygenase; Morocco; Naloxone; Naltrexone; Nanocomposites; Nanomedicine; Nanoparticles; Narcotic Antagonists; Neonicotinoids; Nitric Oxide; Nitro Compounds; Nitrogen; Nitrogen Compounds; Obesity; Obesity, Abdominal; Occupational Exposure; Ontario; Opiate Substitution Treatment; Opioid-Related Disorders; Oryza; Overweight; Oxidative Stress; Oxides; Oxygen; Perception; Photoelectron Spectroscopy; Plants; Plastics; Point Mutation; Polychlorinated Biphenyls; Polycyclic Aromatic Hydrocarbons; Potassium; Premenopause; Prodrugs; Prospective Studies; Protons; Pyrolysis; Qualitative Research; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Resins, Synthetic; Rhodamines; Risk Factors; ROC Curve; Salmo salar; SARS-CoV-2; Seawater; Severity of Illness Index; Sewage; Social Media; Soil; Soil Microbiology; Soil Pollutants; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis, Raman; Staining and Labeling; Stainless Steel; Steel; Stress, Physiological; Substance Abuse Treatment Centers; Symporters; T-Lymphocytes; Toluene; Triclosan; Ultraviolet Rays; Waist Circumference; Waste Disposal, Fluid; Wastewater; Water Purification; Welding; X-Ray Diffraction; Young Adult | 2020 |
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Topics: Animals; Anti-Obesity Agents; Benzazepines; Bupropion; Humans; Liraglutide; Naltrexone; Obesity; Orlistat; Overweight; Phentermine; Topiramate; United States; United States Food and Drug Administration; Weight Loss | 2021 |
Naltrexone ER/Bupropion ER: A Review in Obesity Management.
Topics: Adult; Animals; Anti-Obesity Agents; Bupropion; Delayed-Action Preparations; Drug Combinations; Humans; Naltrexone; Obesity; Overweight | 2015 |
Combination therapy with naltrexone and bupropion for obesity.
Topics: Animals; Bupropion; Dopamine Uptake Inhibitors; Drug Combinations; Humans; Naltrexone; Narcotic Antagonists; Obesity; Overweight; Weight Loss | 2011 |
ACS chemical neuroscience molecule spotlight on contrave.
Topics: Anti-Obesity Agents; Bupropion; Clinical Trials, Phase III as Topic; Double-Blind Method; Drug Approval; Drug Combinations; Humans; Naltrexone; Obesity; Overweight; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration; Weight Loss | 2011 |
9 trial(s) available for naltrexone and Overweight
| Article | Year |
|---|---|
A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II).
Topics: Adult; Anti-Obesity Agents; Bupropion; Cardiovascular Diseases; Delayed-Action Preparations; Dopamine Uptake Inhibitors; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Feeding Behavior; Female; Humans; Hypertension; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nausea; Obesity; Overweight; Quality of Life; Risk Factors; Weight Loss | 2013 |
Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Clinical Protocols; Double-Blind Method; Female; Humans; Male; Mental Disorders; Middle Aged; Naltrexone; Narcotic Antagonists; Overweight; Psychotic Disorders; Research Design; Schizophrenia; Weight Gain; Weight Loss | 2013 |
Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Blood Glucose; Body Weight; Bupropion; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Obesity; Overweight; Retrospective Studies; Risk Factors; Treatment Outcome; Weight Loss; Young Adult | 2013 |
Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial.
Topics: Aged; Anti-Obesity Agents; Blood Pressure; Body Mass Index; Bupropion; Cardiovascular Diseases; Confidence Intervals; Confidentiality; Double-Blind Method; Drug Therapy, Combination; Early Termination of Clinical Trials; Female; Humans; Internet; Male; Middle Aged; Myocardial Infarction; Naltrexone; Obesity; Overweight; Patient Selection; Placebo Effect; Risk Factors; Sample Size; United States; Weight Reduction Programs | 2016 |
Naltrexone/Bupropion extended release-induced weight loss is independent of nausea in subjects without diabetes.
Topics: Adult; Anti-Obesity Agents; Body Mass Index; Bupropion; Combined Modality Therapy; Delayed-Action Preparations; Drug Therapy, Combination; Dyslipidemias; Female; Humans; Hypertension; Incidence; Lost to Follow-Up; Male; Naltrexone; Nausea; Obesity; Overweight; Patient Dropouts; Severity of Illness Index; United States; Weight Loss | 2016 |
Rational design of a combination medication for the treatment of obesity.
Topics: Adult; Animal Feed; Animals; Antidepressive Agents; Bupropion; Disease Models, Animal; Drug Therapy, Combination; Fasting; Female; Humans; Male; Mice; Mice, Obese; Naltrexone; Narcotic Antagonists; Obesity; Overweight; United States; Weight Loss | 2009 |
An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects.
Topics: Adult; Bupropion; Cotinine; Counseling; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Obesity; Overweight; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Treatment Outcome; Weight Gain | 2010 |
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Adult; Anti-Obesity Agents; Bupropion; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Obesity; Overweight; Weight Loss | 2010 |
Smoke and mirrors: magnified beliefs that cigarette smoking suppresses weight.
Topics: Adult; Culture; Feeding Behavior; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Overweight; Psychiatric Status Rating Scales; Self Concept; Smoking; Smoking Cessation; Weight Gain | 2007 |
7 other study(ies) available for naltrexone and Overweight
| Article | Year |
|---|---|
Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6-month long
Topics: Bupropion; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Glucagon-Like Peptides; Humans; Liraglutide; Naltrexone; Obesity; Overweight; Peptides; Proglucagon; Weight Loss | 2023 |
Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or Obese Subjects with Major Depressive Disorder in an Open-Label, Uncontrolled Study.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Binge-Eating Disorder; Bupropion; Comorbidity; Depressive Disorder, Major; Female; Humans; Middle Aged; Naltrexone; Narcotic Antagonists; Obesity; Overweight | 2017 |
Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion combination therapy: a pooled analysis.
Topics: Anti-Obesity Agents; Bupropion; Double-Blind Method; Drug Combinations; Humans; Mood Disorders; Naltrexone; Obesity; Overweight; Prospective Studies; Randomized Controlled Trials as Topic | 2019 |
Therapies for obesity and medication-associated weight gain.
Topics: Animals; Appetite Depressants; Bariatric Surgery; Benzazepines; Bupropion; Chronic Disease; Combined Modality Therapy; Diet, Reducing; Disease Models, Animal; Drug Combinations; Exercise; Fructose; Humans; Mood Disorders; Naltrexone; Obesity; Overweight; Phentermine; Psychotic Disorders; Randomized Controlled Trials as Topic | 2013 |
A new biomarker of hedonic eating? A preliminary investigation of cortisol and nausea responses to acute opioid blockade.
Topics: Adiposity; Adult; Biomarkers; Body Mass Index; Bulimia; Cross-Sectional Studies; Eating; Energy Intake; Feeding Behavior; Female; Humans; Hydrocortisone; Middle Aged; Naltrexone; Narcotic Antagonists; Nausea; Obesity; Overweight; Receptors, Opioid; Surveys and Questionnaires | 2014 |
[Mysimba, an American appetite suppressant and the logic of the single European market].
Topics: Anti-Obesity Agents; Bupropion; Drug Combinations; Humans; Naltrexone; Obesity; Overweight | 2015 |
Answers to Clinical Questions in the Primary Care Management of People with Obesity: Pharmacologic Management.
Topics: Anti-Obesity Agents; Benzazepines; Body Mass Index; Bupropion; Guidelines as Topic; Humans; Lactones; Life Style; Liraglutide; Naltrexone; Obesity; Orlistat; Overweight; Phentermine; Primary Health Care; Risk Factors; Treatment Outcome; Weight Loss | 2016 |